The FIRST and ONLY oral CGRP receptor antagonist indicated in the prevention of migraine in adults1,2*
QULIPTA: Designed to block CGRP binding to its receptor1†
Adapted from the QULIPTA Product Monograph.
●QULIPTA is an orally administered, small-molecule, selective CGRP-receptor antagonist.
●QULIPTA blocks the binding of the CGRP to its receptor.
●CGRP is a neuropeptide that may play a role in migraine pathophysiology.
Pharmacokinetics: Elimination Half-Life
QULIPTA has a half-life of ~11 hours.
Safety information
Click here for additional safety information and for a link to the Product Monograph discussing:
●Relevant warnings and precautions regarding patients with severe hepatic impairment, driving and operating machinery, pregnant and nursing women, and geriatrics.
●Conditions of clinical use, adverse reaction, drug interactions and dosing instructions.
References:
1. QULIPTA Product Monograph. AbbVie Corporation.
2. Data on File. AbbVie Corporation.
CGRP: calcitonin gene-related peptide.
* Comparative clinical significance has not been established.
† Clinical significance has not been established.
For more information
For any questions related to QULIPTA, you can contact AbbVie Medical Information at 1 844 241-5011.
QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.
CGRP: calcitonin gene-related peptide.
* Comparative clinical significance has not been established.
† Clinical significance has not been established.
For more information
For any questions related to QULIPTA, you can contact AbbVie Medical Information at
1 844 241-5011.
QULIPTA and its design are trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company, used under license by AbbVie Corporation.
© 2024 AbbVie. All rights reserved.
CA-QLP-240063A / OC24